Fibroblasts and associated extracellular matrix components at wound site

Fibroblasts and the associated extracellular matrix (ECM) components at a wound site constitute a dynamic microenvironment essential for tissue repair and regeneration. Upon injury, fibroblasts are recruited to the site and activated into myofibroblasts, which synthesize and remodel ECM proteins such as collagen, elastin, and fibronectin to provide structural integrity to the healing tissue (StatPearls, 2023). This environment is tightly regulated by various growth factors, most notably Transforming Growth Factor-beta (TGF-β), which drives the transition from the inflammatory phase to the proliferative phase of wound healing (PubMed, 2021). Dysregulation of this complex system can lead to pathological conditions, such as chronic non-healing wounds in diabetic patients or excessive scarring and fibrosis (NIH, 2022). Therapeutic strategies often focus on specific molecular targets within this niche, such as Platelet-Derived Growth Factor (PDGF) receptors or collagen-degrading enzymes, to accelerate closure or prevent hypertrophic scars (Journal of Clinical Investigation, 2020). While not a single molecular target, this cellular and structural complex is a critical focus for regenerative medicine and anti-fibrotic drug development.

Other names

Wound bedGranulation tissueFibroblast-ECM nicheMyofibroblasts and wound matrixHealing tissue microenvironment

Drugs targeting this environment typically modulate fibroblast activation, promote enzymatic degradation of excess extracellular matrix proteins, or deliver exogenous growth factors to stimulate cellular proliferation and tissue remodeling.